CCI Welcomes ERM, Internal Audit Columnists

After introducing three new columnists in June, Corporate Compliance Insights is proud to introduce two more new expert columnists that will bring more value and insight into their areas of expertise.

Jim DeLoach, Protiviti, ERM SpecialistJim DeLoach of Protiviti,

Making Enterprise Risk Management Work

Jim DeLoach is managing director at at Protiviti, a global business consulting and internal audit firm. He has more than 35 years of experience and is a member of the Protiviti Solutions Leadership Team. His market focus is on helping organizations succeed in responding to government mandates, shareholder demands and a changing business environment in a cost-effective and sustainable manner that reduces risk to an acceptable level. He also assists companies with integrating risk management with strategy setting and performance management. Jim also serves as a member of Protiviti’s Executive Council to the CEO.

For Jim’s first article in his Making Enterprise Risk Management Work column, he discusses What Is ERM and Why Is It Important?

warren stippich grant thorntonWarren Stippich of Grant Thornton,

Internal Audit Revolution

Warren W. Stippich Jr. is Partner and the National Governance, Risk and Compliance Solution Leader at Grant Thornton LLP and the Market Leader of the Chicago Business Advisory Services Group. He has over 20 years experience working with multi-national, entrepreneurial, and high-growth public companies, including boards of directors and audit committees. Warren brings experience to the business risk consulting and internal audit services areas from both the public accounting firm and industry perspectives.

Warren poses the question, Does Your Internal Audit Department Span the Globe? Should It? in his debut article for his Internal Audit Revolution column.

About the Author

Lindsey Perkins Wade

Sarah-K.-GiestingSarah K. Giesting is an associate in the Health Care and Life Sciences Practice in the firm's New York office. Ms. Giesting's practice focuses on compliance and regulatory issues within the pharmaceutical, medical device, and biotechnology industries. Ms. Giesting's experience includes:

  • Counseling clients on state and federal health care fraud and abuse issues, compliance and regulatory parameters, and industry guidance, including sales and marketing practices, consulting relationships, grants, CME programs, and off-label promotion
  • Representing health care entities in connection with government investigations, inquiries, and settlements
  • Developing and implementing corporate compliance programs and compliance training programs
  • Advising on state and federal marketing and disclosure laws
  • Conducting internal compliance reviews and investigations
  • Conducting health regulatory due diligence for transactions in the life sciences industry
Ms. Giesting frequently writes and speaks on topics impacting pharmaceutical, medical device, and biotechnology companies. Prior to joining Epstein Becker Green, Ms. Giesting was a Compliance Specialist, Senior Consultant at a New York-based consulting firm, where she offered compliance guidance to pharmaceutical, medical device, and biotechnology companies. Her experiences include serving as a member of the Independent Review Organization (IRO) for a major pharmaceutical company.